Jefferies keeps Buy rating for GSK stock at GBp 2,500.00 target

Published on 10/06/2026 at 10:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter turnover rose 5.00 percent to GBP 8.41 billion in 2026. GSK stock costs EUR 20.90 on October 6, 2026 after EUR 20.74.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock (ISIN GB00BN7SWP63) was trading at EUR 20.90 at Lang & Schwarz on October 6, 2026 at 10:08 a.m. CEST, up 0.77 percent versus the prior close of EUR 20.74. Jefferies maintained a Buy rating and a GBp 2,500.00 price target for GSK in a note dated September 29, 2026, according to finanzen.ch.

Jefferies keeps its target

The target is stated in pence because GSK's primary listing is on the London Stock Exchange. A master-data page identifies GSK plc, ticker GSK.L, the LSE listing and ISIN GB00BN7SWP63, according to Global Banking and Finance.

Jefferies' GBp 2,500.00 target stands above the current LSE quote cited in the analyst overview, while the recommendation remains Buy. That combination gives the market a clear valuation reference, but the target is separate from the EUR 20.90 Lang & Schwarz price and cannot be converted into a euro percentage without a matching exchange rate.

Second-quarter sales grew

GSK reported second-quarter 2026 turnover of GBP 8.41 billion, up 5.00 percent from the second quarter of 2025, according to StockTitan. Specialty Medicines increased 14.00 percent to GBP 3.78 billion and Vaccines increased 9.00 percent to GBP 2.28 billion, whereas General Medicines declined 9.00 percent to GBP 2.34 billion.

The earnings mix was less favorable. Total operating profit fell 76.00 percent to GBP 481.0 million in the second quarter of 2026, while total earnings per share declined 69.00 percent to GBp 10.80. Core earnings per share rose to GBp 50.50 from GBp 46.50, showing why reported profit and underlying performance point in different directions.

Third-quarter results are dated

MarketBeat lists October 28, 2026, as GSK's third-quarter 2026 reporting date, with expected revenue of USD 11.95 billion, according to MarketBeat. That date gives investors the next scheduled checkpoint for assessing whether Specialty Medicines and Vaccines can offset pressure in General Medicines.

For the October 28 release, the key comparison will be the balance between sales growth and reported profitability. The second-quarter figures already show the tension: turnover grew 5.00 percent, but total operating profit fell 76.00 percent after impairment and other charges.

GSK stock stays in trading

At Lang & Schwarz, GSK stock was trading at EUR 20.90 on October 6, 2026 at 10:08 a.m. CEST, plus 0.77 percent versus the prior close of EUR 20.74 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of GSK stock.